Lien, Scott C. http://orcid.org/0009-0005-0744-4768
Ly, Dalam http://orcid.org/0000-0002-1177-0225
Yang, S. Y. Cindy
Wang, Ben X.
Clouthier, Derek L.
St. Paul, Michael http://orcid.org/0000-0002-5213-6415
Gadalla, Ramy
Noamani, Babak
Garcia-Batres, Carlos R. http://orcid.org/0009-0005-2447-0685
Boross-Harmer, Sarah
Bedard, Philippe L. http://orcid.org/0000-0002-6771-2999
Pugh, Trevor J. http://orcid.org/0000-0002-8073-5888
Spreafico, Anna http://orcid.org/0000-0002-3034-3042
Hirano, Naoto
Razak, Albiruni R. A.
Ohashi, Pamela S. http://orcid.org/0000-0003-2915-9317
Funding for this research was provided by:
Terry Fox Foundation (Terry Fox Translational Research Program iTNT #1060)
Terry Fox Research Institute (New Frontiers Program TFRI # 1064)
Article History
Received: 12 April 2023
Accepted: 22 January 2024
First Online: 6 February 2024
Competing interests
: D.L.C. is currently an employee of AstraZeneca and had been employed by Ipsen and Pfizer after his involvement in this project. T.J.P. provides consultation for Illumina, Merck, Chrysalis Biomedical Advisors and the Canadian Pension Plan Investment Board (compensated); and receives research support (institutional) from Roche/Genentech. A.S. provides consultation for Merck (compensated), Bristol-Myers Squibb (compensated), Novartis (compensated), and Oncorus (compensated); and receives research support (institutional) from Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Array Biopharma. N.H. has received research funding from Takara Bio and served as a consultant for Takara Bio. A.R.A.R. provides consultation for Lilly (compensated), Merck (compensated), and Boehringer-Ingelheim (compensated); receives honoraria from Boehringer-Ingelheim; and receives research support (institutional) from CASI Pharmaceuticals, Boehringer-Ingelheim, Lilly, Novartis, Deciphera, Karyopharm, Pfizer, Roche/Genentech, Boston Biomedical, Bristol-Myers Squibb, AstraZeneca/MedImmune, Amgen, GlaxoSmithKline, Blueprint Medicines, Merck, Abbvie, and Adaptimmune. P.S.O. is an SAB member for Symphogen Inc and Providence Therapeutics. P.S.O, A.R.A.R., N.H., D.L. and S.C.L. have filed a provisional patent related to this work (US63/459,683). The remaining authors declare no competing interests.